Our studies raise the interesting possibility of co-targeting glycolysis and mitochondrial metabolism within the heterogeneous tumor population by inhibiting both GLUT1 and PDH, which inhibits both cell viability and invasion (Fig. 8). Here, SLC2A1 is linked to neoplasm.